flucloxacillin

flucloxacillin. It is a narrow-spectrum beta-lactam antibiotic of the penicillin class, specifically an isoxazolyl penicillin. It is primarily used to treat infections caused by susceptible Gram-positive bacteria, notably those producing penicillinase such as Staphylococcus aureus. Developed to be resistant to degradation by bacterial enzymes, it is a first-line agent for skin and soft tissue infections including cellulitis and impetigo, and for prophylaxis in orthopedic surgery.

Medical uses

It is indicated for infections caused by penicillinase-producing staphylococci, including osteomyelitis, septic arthritis, pneumonia, endocarditis, and meningitis. It is often used for surgical prophylaxis, particularly in procedures involving prosthetic joint implantation or cardiac valve surgery, as recommended by guidelines from the National Institute for Health and Care Excellence. It is not effective against infections caused by methicillin-resistant Staphylococcus aureus or most Gram-negative bacteria such as Escherichia coli. Clinical use is typically guided by antimicrobial susceptibility testing from institutions like the Clinical and Laboratory Standards Institute.

Adverse effects

The most common adverse effects involve the gastrointestinal tract, including nausea, diarrhea, and Clostridioides difficile infection. Hypersensitivity reactions can occur, ranging from maculopapular rash to severe anaphylaxis. A serious idiosyncratic reaction is cholestatic hepatitis, which has been associated with prolonged use and reported to regulatory bodies like the Medicines and Healthcare products Regulatory Agency and the Food and Drug Administration. Other potential effects include hemolytic anemia, interstitial nephritis, and neutropenia, with monitoring advised by organizations such as the World Health Organization.

Pharmacology

It acts by inhibiting the synthesis of bacterial cell walls, specifically by binding to penicillin-binding proteins and disrupting the final step of peptidoglycan cross-linking. Its structure includes an isoxazolyl side chain that confers stability against hydrolysis by staphylococcal penicillinase. Pharmacokinetic studies show it is acid-stable, allowing oral administration, with peak concentrations reached within one to two hours. Distribution is throughout body fluids, but penetration into the cerebrospinal fluid is poor unless the meninges are inflamed. It is metabolized in the liver and excreted largely unchanged by the kidney via glomerular filtration and tubular secretion.

History

It was developed in the 1960s by the British company Beecham Group as part of a series of isoxazolyl penicillins that included cloxacillin and dicloxacillin. This research was driven by the urgent need to combat the rising prevalence of penicillinase-producing Staphylococcus aureus strains in hospitals like St Mary's Hospital, London. Its invention followed the pioneering work on penicillin by Alexander Fleming and the mass-production techniques developed during World War II. It received approval for medical use and has been listed on the World Health Organization Model List of Essential Medicines.

Society and culture

It is available under various brand names including Floxapen and is manufactured by several pharmaceutical companies. It is on the World Health Organization Model List of Essential Medicines, highlighting its importance in basic health systems. Regulatory oversight is provided by agencies like the European Medicines Agency and the Therapeutic Goods Administration. Its use is a component of global strategies to combat antimicrobial resistance, promoted by initiatives like the Global Antimicrobial Resistance and Use Surveillance System. Prescribing is often guided by local antimicrobial stewardship programs to ensure appropriate use.

Category:World Health Organization essential medicines Category:Penicillin antibiotics Category:Isoxazoles